Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05787860 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib in Seborrheic Dermatitis
A Phase 2 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT05787860 is a Phase 2 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 45 participants.
The verdict
NCT05787860, a Phase 2 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in healthy control subjects.
Interventions
- DRUG Ruxolitinib 1.5% Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-11-15 |
| Est. Completion | 2024-01-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05787860
The ClinicalTrials.gov registry entry for NCT05787860 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ruxolitinib 1.5% Cream is the first listed.
NCT05787860 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05787860 about?
NCT05787860 is a clinical study titled "Ruxolitinib in Seborrheic Dermatitis". This study is an open-label prospective interventional trial that will assess the efficacy of ruxolitinib in the treatment of seborrheic dermatitis. It will also attempt to characterize the molecular immune profiles of patients with SD at week 0 and week 4, with comparison to baseline profiles in he...
What is the current status of trial NCT05787860?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2022-11-15. Estimated completion is 2024-01-26.
What interventions are being tested in trial NCT05787860?
The interventions under investigation include: Ruxolitinib 1.5% Cream (DRUG).
Who is sponsoring clinical trial NCT05787860?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.